Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to take part (or whose legal representative has done so on their behalf)
• People aged 18 or older
• People whose general health and ability to carry out daily activities meets a certain minimum level, as assessed using a standard medical scale (confirm with trial site)
• People who have a confirmed diagnosis of a type of blood cancer called B-cell chronic lymphocytic leukaemia or small lymphocytic lymphoma (B-CLL/SLL), confirmed through laboratory testing
• People who have not previously received treatment for CLL/SLL, except steroids or a drug called rituximab used to treat immune-related complications
• People whose cancer cells test positive for a protein called CD20
• People whose disease is active and meets recognised international guidelines for needing treatment, shown by at least one of the following: unintentional weight loss of more than 10% in the past 6 months; extreme fatigue that prevents normal activities or work; fevers above 100.5°F lasting 2 or more weeks without infection; night sweats without infection; worsening anaemia or low platelet counts; a significantly enlarged spleen; very large lymph nodes or clusters of nodes; rapidly increasing white blood cell counts; immune-related anaemia or low platelets not responding well to steroids; or cancer involvement in organs such as skin, kidneys, lungs, or spine
• People who are able to swallow tablets or capsules, and who do not have a digestive condition that would prevent the drug from being absorbed
• People whose blood cell counts and organ function results fall within the ranges required by the trial (specific thresholds apply for white blood cells, platelets, liver function, kidney function, and blood clotting — confirm exact values with trial site)
• Women who could become pregnant must have a negative pregnancy test before joining
• Women who could become pregnant must agree to use a highly effective form of contraception (with a failure rate of less than 1% per year, such as hormonal implants, certain combined oral contraceptives, or certain intrauterine devices) or remain abstinent throughout treatment and for a defined period after the last dose of each study drug, and must not donate eggs during this time
• Men must agree to use a condom or remain abstinent throughout treatment and for a defined period after the last dose of each study drug, and must not donate sperm during this time; men with a pregnant partner must remain abstinent or use a condom for the duration of the pregnancy

Who may not be able to join:

• People who regularly take high-dose steroid medication (more than the equivalent of 20 mg per day of prednisone)
• People who have had major surgery requiring general anaesthesia within 30 days before the trial starts
• People with an uncontrolled blood clotting or bleeding disorder (note: certain blood-thinning tablets are permitted — confirm with trial site)
• People who have received a live vaccine within 30 days before the trial starts, or who are expected to need one during treatment
• People whose CLL/SLL has transformed into a more aggressive type of lymphoma (known as Richter's transformation)
• People whose cancer has spread to the central nervous system (brain or spinal cord)
• People with a history of a serious brain condition called progressive multifocal leukoencephalopathy (PML)
• People with a history of another cancer, unless it was treated with curative intent and has shown no signs of returning for at least 2 years, or it was a type of skin cancer or pre-cancerous condition that was adequately treated with no current signs of disease, or it is prostate cancer being monitored without active treatment
• People with uncontrolled immune-related destruction of blood cells (red blood cells or platelets)
• People with an active, uncontrolled infection
• People with active hepatitis C infection (those with past exposure but no detectable virus may still be considered — confirm with trial site)
• People with active chronic hepatitis B infection (those with past or hidden infection may be considered if the virus is undetectable and they agree to ongoing monitoring — confirm with trial site)
• People living with HIV may be considered only if they are on effective HIV treatment, have undetectable HIV levels, and have no HIV-related complications — confirm with trial site
• Women who are pregnant or breastfeeding
• People with any other medical condition that the trial doctor believes would make participation unsafe
• People who, in the trial doctor's judgement, may not be able to follow the trial procedures reliably

Important: Always verify eligibility with the trial site directly before applying.